Chronic lymphocytic leukemia: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(47 intermediate revisions by 14 users not shown)
Line 1: Line 1:
__NOTOC__
{{Chronic lymphocytic leukemia}}
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
{{Infobox_Disease |
  Name          = {{PAGENAME}} |
  Image          = Chronic_lymphocytic_leukemia.jpg |
  Caption        = Peripheral blood smear showing CLL cells |
  DiseasesDB    = 2641 |
  ICD10          = {{ICD10|C|91|1|c|81}} |
  ICD9          = {{ICD9|204.9}} |
  ICDO          = 9823/3 |
  OMIM          = |
  MedlinePlus    = 000532|
  MeshID        = D015462 |
}}
{{SI}}
{{CMG}}
{{Editor Help}}
==Overview==
'''Chronic lymphocytic leukemia''' (also known as "chronic lymphoid leukemia" or "CLL"), is a type of [[leukemia]], or cancer of the white blood cells ([[lymphocytes]]). CLL affects a particular lymphocyte, the [[B cell]], which originates in the bone marrow, develops in the lymph nodes, and normally fights infection. In CLL, the DNA of a B cell is damaged, so that it can't fight infection, but it grows out of control and crowds out the healthy blood cells that can fight infection.
CLL is an abnormal neoplastic proliferation of B cells. The cells accumulate mainly in the bone marrow and blood. CLL is closely related to a disease called [[small lymphocytic lymphoma]] (SLL), a type of [[non-Hodgkin's lymphoma]] which presents primarily in the [[lymph nodes]].  The [[World Health Organization]] considers CLL and SLL to be "one disease at different stages, not two separate entities".<ref name="pmid10577857">{{cite journal |author=Harris NL, Jaffe ES, Diebold J, ''et al'' |title=World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 |journal=J. Clin. Oncol. |volume=17 |issue=12 |pages=3835-49 |year=1999 |pmid=10577857 |doi=}}</ref>


In the past, cases with similar microscopic appearance in the blood but with a T cell phenotype were referred to as T-cell CLL. However, it is now recognized that these so-called T-cell CLLs are in fact a separate disease group and are currently classified as [[T-cell prolymphocytic leukemia]]s.
{{CMG}}; {{AE}} {{S.S}}, {{HL}}


[[Acute lymphocytic leukemia]] (ALL) is a disease of children, but CLL is a disease of adults. Most (>75%) people newly diagnosed with CLL are over age 50, and two-thirds are men. In the United States during 2007, it is estimated there will be 15,340 new cases diagnosed and 4,500 deaths<ref name="NCI-CLL-page1">{{cite web |url=http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page1 |title=Chronic Lymphocytic Leukemia (PDQ®) Treatment: General Information |author=National Cancer Institute |accessdate=2007-09-04 |format= |work=}}</ref>, but because of prolonged survival, many more people are living with CLL.
{{SK}} CLL; Small Lymphocytic Lymphoma; B-cell Chronic Lymphocytic Leukemia; B cell Chronic Lymphocytic Leukemia


Most people are diagnosed without symptoms as the result of a routine blood test that returns a high white blood cell count, but as it advances CLL results in [[swollen lymph nodes]], [[splenomegaly|spleen]], and [[hepatomegaly|liver]], and eventually [[anemia]] and infections. Early CLL is not treated, and late CLL is treated with chemotherapy and monoclonal antibodies. Survival varies from 5 years to more than 25 years. It is now possible to diagnose patients with short and long survival more precisely by examining the DNA mutations, and patients with slowly-progressing disease can be reassured and may not need any treatment in their lifetimes.<ref name="pmid15728813">{{cite journal |author=Chiorazzi N, Rai KR, Ferrarini M |title=Chronic lymphocytic leukemia |journal=N. Engl. J. Med. |volume=352 |issue=8 |pages=804-15 |year=2005 |pmid=15728813 |doi=10.1056/NEJMra041720}}</ref>
==[[Chronic lymphocytic leukemia overview|Overview]]==  


==Classification and prognosis==
==[[Chronic lymphocytic leukemia historical perspective|Historical Perspective]]==
===Clinical staging===
Staging is done with the Rai staging system and the Binet classification (see details<ref name="NCI-CLL-page2">{{cite web |url=http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page2 |title=Chronic Lymphocytic Leukemia (PDQ®) Treatment: Stage Information |author=National Cancer Institute |accessdate=2007-09-04 |format= |work=}}</ref>).


===Gene mutation status===
==[[Chronic lymphocytic leukemia classification|Classification]]==
Recent publications suggest that two<ref name="pmid11733578">{{cite journal |author=Rosenwald A, Alizadeh AA, Widhopf G, ''et al'' |title=Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia |journal=J. Exp. Med. |volume=194 |issue=11 |pages=1639-47 |year=2001 |pmid=11733578 |doi=}}</ref> or three<ref name="pmid12406914">{{cite journal |author=Ghia P, Guida G, Stella S, ''et al'' |title=The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression |journal=Blood |volume=101 |issue=4 |pages=1262-9 |year=2003 |pmid=12406914 |doi=10.1182/blood-2002-06-1801}}</ref> prognostic groups of CLL exist based on the maturational state of the cell. This distinction is based on the maturity of the lymphocytes as discerned by the immunoglobulin variable-region [[heavy chain]] (IgV<sub>H</sub>) gene mutation status.<ref name="pmid16983131">{{cite journal |author=Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE |title=Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia |journal=Ann. Intern. Med. |volume=145 |issue=6 |pages=435-47 |year=2006 |pmid=16983131 |doi=|url=http://www.annals.org/cgi/content/full/145/6/435}}</ref>  High risk patients have an immature cell pattern with few mutations in the DNA in the IgV<sub>H</sub> antibody gene region whereas low risk patients show considerable mutations of the DNA in the antibody gene region indicating mature lymphocytes.


Since assessment of the IgV<sub>H</sub> antibody DNA changes is difficult to perform, the presence of either [[cluster of differentiation]] [[CD38|38]] ([[CD38]]) or Z-chain–associated protein kinase-70 ([[ZAP-70]]) may be surrogate markers of high risk subtype of CLL.<ref name="pmid16983131"/> Their expression correlates with a more immature cellular state and a more rapid disease course.  Unmutated IGVH survive worse than mutated and are associated with aggressive CLL.  The ZAP70 (AKA Zeta-Associated Protein) presence on the CLL cell correlates with unmutated immunoglobulin genes and a poor prognosis.  Conversely, its absence indicates the presence of mutated genes and a good clinical outcome.  Patients positive for ZAP70 have a CLL more aggressive in nature and more refractory to treatment.  They are more likely to evolve to more unfavorable cytogenetic abnormalitites. 
==[[Chronic lymphocytic leukemia pathophysiology|Pathophysiology]]==


===Fluorescence in situ hybridization (FISH)===
==[[Chronic lymphocytic leukemia causes|Causes]]==
In addition to the maturational state, the prognosis of patients with CLL is dependent on the genetic changes within the neoplastic cell population. These genetic changes can be identified by fluorescent probes to chromosomal parts using a technique referred to as [[fluorescent in situ hybridization]] (FISH).<ref name="pmid16983131"/> Compared with fluorescence in-situ hybridization (FISH), conventional metaphase cytogenetics play ONLY a MINOR prognostic role in CLL, so far, due to technical problems resulting from a limited proliferation of CLL cells in-vitro.  Therefore conventional cytogenetics  may define subgroups with a high risk of progression.  FISH can be done (in CLL) on dividing and non-dividing cells.  FISH doesn't tell about IgVH mutations nor does it define the presence of trisomy either.  FISH is useful as long as there are CLL cells to test; you can't do it in a complete response (CR).The application of FISH to study interphase nuclei gives important prognostic information with B-cell CLL, especially for patients with 11q-, trisomy 12, 13q- and 17q-.   
The procedure of FISH involves cell cultures which are prepared after metaphase and prometaphase chromosomes are fixed to a glass slide.  A DNA probe is then hybridized onto the chromosome; the probe is labeled with fluorochrome which can be detected with fluorescent microscopy.  FISH can be done on dividing and non-dividing cells.  Inversions will be missed as probes detect sequences not precise locations.  Small mutations, such as small deletions and insertions, will also be missed.  FISH is a cytogenetic technology that looks at 200-500 blood cells (obtained with a bone marrow biopsy).  Because of the small size it is not as sensitive as PCR.  (PCR has extreme sensitivity as well as being quite specific). 
PCR amplifies a fragment of DNA.  It is at least 2-3 logs more sensitive than cytogenetic technology like FISH.  PCR measurement requires a sample blood draw which is less invasive and intense than a bone marrow biopsy (with FISH). 
Four main genetic aberrations are recognized in CLL cells that have a major impact on disease behavior.
# Deletions of part of the short arm of chromosome 17 (del 17p13) which target the cell cycle regulating protein p53 (a tumore suppressor gene) are particularly deleterious. Patients with this abnormality have significantly short interval before they require therapy and a shorter survival. This abnormality is found in 5-10% of patients with CLL.
# Deletions of the long arm on chromosome 11 (del 11q22-q23) are also unfavorable although not to the degree seen with del 17p. The abnormality targets the ATM gene and occurs infrequently in CLL (5-10%).
# Trisomy 12, an additional chromosome 12, is a relatively frequent finding occurring in 20-25% of patients and imparts an intermediate prognosis.  It has a higher frequency of DNA aneuploidy. 
# Deletion of the long arm of chromosome 13 (del 13q14) is the most common abnormality in CLL with roughly 50% of patients with cells containing this defect. These patients (along with those of normal karyotype) have the best prognosis and most will live many years, even decades, without the need for therapy. The gene targeted by this deletion is a segment that likely produces small inhibitory RNA molecules that affect expression of important death inhibiting genes.


The presence of 17p- typifies cells that are resistant to fludarabine, alkylators and rituxumab. 
==[[Chronic lymphocytic leukemia differential diagnosis|Differentiating Chronic lymphocytic leukemia from other Diseases]]==
11q- portends a decreased RR to fludrabine as well as an early relapse after bone marrow transplant (BMT). 
Both the 17p- and the 11q- have a decreased progression-free survival (PFS) and overall survival (OS). 


==Symptoms and signs==
==[[Chronic lymphocytic leukemia epidemiology and demographics|Epidemiology and Demographics]]==
Most people are diagnosed without symptoms as the result of a routine blood test that returns a high white blood cell count, but as it advances CLL results in swollen lymph nodes, spleen, and liver, and eventually anemia and infections.


Uncommonly, CLL presents as enlargement of the lymph nodes without a high white blood cell count or no evidence of the disease in the blood. This is referred to as [[small lymphocytic lymphoma]].
==[[Chronic lymphocytic leukemia risk factors|Risk Factors]]==


The increase in lymphocytes and precursors in the bone marrow impairs the production of other [[leucocytes]] causing a decrease in such cell types.
==[[Chronic lymphocytic leukemia screening|Screening]]==


A high beta-2-microglobulin level  may be seen and is an independent adverse prognostic factor for CR and OS. 
==[[Chronic lymphocytic leukemia natural history, complications and prognosis|Natural History, Complications and Prognosis]]==


==Diagnosis==
==Diagnosis==
CLL is usually first suspected by the presence of a [[lymphocytosis]], an increase in one type of the white blood cell, on a complete blood count (CBC) test. This frequently is an incidental finding on a routine physician visit. Most often the lymphocyte count is greater than 4000 cells per mm3 (microliter) of blood but can be much higher.
[[Chronic lymphocytic leukemia diagnostic study of choice|Diagnostic Study of Choice]] | [[Chronic lymphocytic leukemia clinical staging|Staging]] | [[Chronic lymphocytic leukemia history and symptoms|History and Symptoms]] | [[Chronic lymphocytic leukemia physical examination|Physical Examination]] | [[Chronic lymphocytic leukemia laboratory tests|Laboratory Findings]] | [[Chronic lymphocytic leukemia electrocardiogram|Electrocardiogram]] | [[Chronic lymphocytic leukemia chest x ray|Chest X Ray]] | [[Chronic lymphocytic leukemia CT|CT]] | [[Chronic lymphocytic leukemia MRI|MRI]] | [[Chronic lymphocytic leukemia echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Chronic lymphocytic leukemia other imaging findings|Other Imaging Findings]] | [[Chronic lymphocytic leukemia other diagnostic studies|Other Diagnostic Studies]]
 
===Pathology===
<div align="left">
<gallery heights="175" widths="175">
Image:CLL.jpg|CLL (more cytoplasmic space)<ref>http://picasaweb.google.com/mcmumbi/USMLEIIImages</ref>
Image:CLL Smudge Cell.jpg|CLL Smudge Cell<ref>http://picasaweb.google.com/mcmumbi/USMLEIIImages</ref>
</gallery>
</div>
 
===Determining clonality===
 
The diagnosis of CLL is based on the demonstration of an abnormal population of B lymphocytes in the blood, bone marrow, or tissues that display an unusual but characteristic pattern of molecules on the cell surface. This atypical molecular pattern includes the co-expression of cells surface markers [[cluster of differentiation]] [[CD5 (protein)|5]] ([[CD5 (protein)|CD5]]) and [[cluster of differentiation]] [[CD23|23]] ([[CD23]]). In addition, all the CLL cells within one individual are functionally inert and clonal, that is genetically identical. In practice, this is inferred by the detection of only one of the mutually exclusive [[Light_chain#In_humans|antibody light chains]], kappa or lambda, on the entire population of the abnormal B cells. Normal B lymphocytes consist of a stew of different antibody producing cells resulting in a mixture of both kappa and lambda expressing cells. The lack of the normal distribution of kappa and lambda producing B cells is one basis for demonstrating clonality, the key element for establishing a diagnosis of any B cell malignancy (B cell Non-Hodgkin lymphoma).
 
Clonality is confirmed by the combination of the microscopic examination of the peripheral blood and analysis of the lymphocytes by [[flow cytometry]]. The latter is easily accomplished on a small amount of blood. A [[flow cytometer]] is an instrument that can examine the marker molecule expression on individual cells in fluids. This is accomplished using antibodies with fluorescent tags recognized by the instrument. In CLL, the lymphocytes are genetically clonal, of the B cell lineage (express marker molecules CD19 and CD20), and  characteristically express the marker molecules [[CD5 (protein)|CD5]] and [[CD23]]. Morphologically, the cells resemble normal lymphocytes under the microscope, although slightly larger, and are fragile when smeared onto a glass slide giving rise to many broken cells (smudge cells).
 
===Differential diagnosis===
Hematologic disorders that may resemble CLL in their clinical presentation, behavior, and microscopic appearance include mantle cell lymphoma, marginal zone lymphoma, B cell prolymphocytic leukemia, and lymphoplasmacytic lymphoma.
* [[B cell prolymphocytic leukemia]] (B PLL), which is a related but more aggressive disorder, has cells with similar phenotype but that are signficantly larger than normal lymphocytes and have a prominent nucleolus suggests a related.
* [[Hairy cell leukemia]] is also a neoplasm of B lymphocytes but differs significantly from CLL by its morphology under the microscope ([[hairy cell leukemia]] cells have delicate, hair-like projections on their surface) and  marker molecule expression.
 
All the B cell malignancies of the blood and [[bone marrow]] can be differentiated from one another by the combination of cellular microscopic morphology, marker molecule expression, and specific tumor-associated gene defects. This is best accomplished by evaluation of the patient's blood, bone marrow and occasionally lymph node cells by a [[pathologist]] with specific training in blood disorders. A sophisticated instrument called a [[flow cytometer]] is necessary for cell marker analysis and the detection of genetic problems in the cells may require visualizing the DNA changes with fluorescent probes by [[fluorescent in situ hybridization]] (FISH).
CLL is positive for CD5, CD19 & CD23; CLL is the only cell type that coexpresses CD5 & 19.  It is negative for CD10 & cyclin D.
CD20 is +/- as is sIg.  90% of B-CLL have bcl-2. 
The 2 most noteworthy lymphoproliferative diseases with CD5 positivity are CLL (which is CD23 positive) & mantle zone lymphoma (which is CD23 negative).  Other CD5+ groups include peripheral & cutaneous T-cell lymphoma, lymphoblastic lymphoma, and Adult T-cell leukemia/lymphoma. 


==Treatment==
==Treatment==
While generally considered incurable, CLL progresses slowly in most cases. Many people with CLL lead normal and active lives for many years - in some cases for decades. Because of its slow onset, early-stage CLL is generally not treated since it is believed that early CLL intervention does not improve survival time or quality of life. No chemotherapy has clearly prolonged survival in CLL.  Instead, the condition is monitored over time.
[[Chronic lymphocytic leukemia medical therapy|Medical therapy]] | [[Chronic lymphocytic leukemia surgery|Surgery]] | [[Chronic lymphocytic leukemia primary prevention|Primary prevention]] | [[Chronic lymphocytic leukemia secondary prevention|Secondary prevention]] | [[Chronic lymphocytic leukemia cost-effectiveness of therapy|Cost-effectiveness of therapy]] | [[Chronic lymphocytic leukemia future or investigational therapies|Future or Investigational Therapies]]
The decision to start CLL treatment is taken when the patient's clinical symptoms or blood counts indicate that the disease has progressed to a point where it may affect the patient's quality of life.
CLL treatment focuses on controlling the disease and its symptoms rather than on an outright cure. CLL is treated by [[chemotherapy]], [[radiation therapy]], [[biological therapy]], or [[bone marrow transplantation]]. Symptoms are sometimes treated surgically ([[splenectomy]] with removal of the enlarged spleen) or by [[radiation therapy]].
 
Clinical "staging systems" such as the Rai 4-stage system and the Binet classification can help to determine when and how to treat the patient.<ref  name="NCI-CLL-page2"/>
 
Determining when to start treatment and by what means is often difficult; studies have shown there is no survival advantage to treating the disease too early. The National Cancer Institute Working Group has issued guidelines for treatment, with specific markers that should be met before it is initiated.<ref name="pmid8652811">{{cite journal |author=Cheson BD, Bennett JM, Grever M, ''et al'' |title=National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment |journal=Blood |volume=87 |issue=12 |pages=4990-7 |year=1996 |pmid=8652811 |doi=}}</ref>
 
Initial CLL treatments vary depending on the exact diagnosis and the progression of the disease, and even with the preference and experience of the health care practitioner. There are dozens of agents used for CLL therapy, and there is considerable research activity studying them individually or in combination with each other.<ref>{{cite web |url=http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page5 |title=Chronic Lymphocytic Leukemia (PDQ®) Treatment: Stage I, II, III, and IV Chronic Lymphocytic Leukemia|author=National Cancer Institute |accessdate=2007-09-04 |format= |work=}}</ref> 
 
CLL (+12) has the capacity for autoimmune cytopenias.  Although about 20% of patients have Coombs positivity only about 8% actually develop hemolytic anemia and about 20% have decreased platelets as well. For warm autoimmune hemolytic anemia give steroids initially, using immunoglobulin secondarily. Cyclosporine is used if steroids and IV-IgG fail.  One might also consider Alemtuzumab +/- fludarabine or cytoxan with dexamethasone.  For refractory AIHA do splenectomy or splenic irradiation.


Corticosteroids are first-line agents for people in whom the immune systems has been altered by CLL. CLL may cause autoimmune syndromes in which the patient's immune system attacks and destroys his or her own blood cells. When the red blood cells are affected, the condition is known as immunohemolytic anemia, characterized by decreased numbers of red blood cells, which may cause fatigue, dizziness, and shortness of breath. When the blood platelets are affected, it is called immune-mediated thrombocytopenia, in which a decreased numbers of platelets may lead to bleeding.
==Case Studies==


For younger patients who are experiencing symptoms, the physician may consider early chemotherapy, plus allogeneic or autologous bone marrow transplantation (alloBMT; autoBMT).
[[Chronic lymphocytic leukemia case study one|Case #1]]
 
In general, the indications for treatment are:
 
* falling hemoglobin or platelet count
* progression to a later stage of disease
* painful, disease-related overgrowth of lymph nodes or spleen
* lymphocyte doubling time (an indicator of lymphocyte reproduction) of fewer than 12 months
===Alkylators===
Chlorambucil (CHB) should be considered for older patients (>90 years) with severe comorbidities (eg renal insufficiency) where they're likely to live less than a year regardless of treatment.  CHB is associated with a median survival of about 2 years in patients with advanced stage CLL; a higher response rate (RR) may be achieved with more aggressive treatment regimens such as CHOP but without any clear survival advantage.  This agent has been replaced by newer agents.  Cytoxan, Oncovin, Prednisone (COP) is not superior to CHB alone, either in complete response rate (CR) or prolonged survival.  CHOP does improve the RR to stage B patients but, again, with no survival advantage. 
 
Bendamustine (treanda) is used in the treatment of CLL (& indolent NHL) that has progressed within 6 months after treatment with Rituxumab.  Administer as 100 mg/m2 / 30" on days 1+2 of a 28 day cycle; up to 6 cycles.  Bendamustine is superior to chlorambucil in the treatment of CLL.  Bendamustine is also given with Ritux for relapsed CLL with the overall response rate (ORR) dependent on chromosomal subtype; 11p deletion = 92%, trisomy 12 = 100%, 17p deletion = 44%, umutated IgVH = 74%. 
 
===Purine analogues===
Although the purine analogue [[fludarabine]] was shown to give superior response rates than [[chlorambucil]] as primary therapy,<ref name="pmid11114313">{{cite journal |author=Rai KR, Peterson BL, Appelbaum FR, ''et al'' |title=Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia |journal=N. Engl. J. Med. |volume=343 |issue=24 |pages=1750-7 |year=2000 |pmid=11114313 |doi=}}</ref><ref name="pmid16856041">{{cite journal |author=Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R |title=Purine antagonists for chronic lymphocytic leukaemia |journal=Cochrane database of systematic reviews (Online) |volume=3 |issue= |pages=CD004270 |year=2006 |pmid=16856041 |doi=10.1002/14651858.CD004270.pub2}}</ref>
there is no evidence that early use of fludarabine improves overall survival. Fludara can actually make CLL-AIHA worse.  It is indicated for patients who have refractory and / or relapsed disease refractory to alkylating agents.  Adding prednisone to fludarabine does not increase the RR over fludarabine alone.  Add prednisone to fludara only in the presence of autoimmune anemia or thrombocytopenia.  Note that fludara with steroids increases the likelihood of P. carinii & Listeria infection.  Patients who fail to respond to fludarabine after 2-3 courses should not receive additional courses.  No further treatment is indicated if a CR has been achieved; otherwise 2 courses are given after the maximal response is achieved, not to exceed one year. 
 
===Combination chemotherapy===
 
Combination chemotherapy options are effective in both newly-diagnosed and relapsed CLL. Recently, randomized trials have shown that combinations of purine analogues (fludarabine) with alkylating agents (cyclophosphamide) produce higher response rates and a longer progression-free survival than single agents:
 
* [[fludarabine]] with [[cyclophosphamide]] <ref name="pmid16219797"> {{cite journal |author=Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M, German CLL Study Group. |title=Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia |journal=Blood |year=2006 |volume=107 |pages=885-91.|pmid16219797}} </ref>
* [[fludarabine]] with [[rituximab]]<ref name="pmid12393429">{{cite journal |author=Byrd JC, Peterson BL, Morrison VA, ''et al'' |title=Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) |journal=Blood |volume=101 |issue=1 |pages=6-14 |year=2003 |pmid=12393429 |doi=10.1182/blood-2002-04-1258}}</ref>   
* FCR ([[fludarabine]], [[cyclophosphamide]], and [[rituximab]])<ref name="pmid15767648">{{cite journal |author=Keating MJ, O'Brien S, Albitar M, ''et al'' |title=Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia |journal=J. Clin. Oncol. |volume=23 |issue=18 |pages=4079-88 |year=2005 |pmid=15767648 |doi=10.1200/JCO.2005.12.051}}</ref>  FCR are well tolerated in previously treated CLL.  However most of their toxicity is myelosuppression.  FCR had a high CR rate (25%), nodular PR (16%) & PR (32%).  Molecular remissions are obtained in 1/3 of patients. 
* CHOP ([[cyclophosphamide]], [[doxorubicin]], [[vincristine]] and [[prednisolone]])
 
===Stem cell transplantion===
Allogeneic [[Stem cell transplantation|bone marrow (stem cell) transplantation]] is rarely used as a first-line treatment for CLL due to its risk. There is increasing interest in the use of reduced intensity allogeneic stem cell transplantation, which offers the prospect of cure for selected patients with a suitable donor.<ref name="Dreger">{{cite journal | author=Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT | title=Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning | journal=Leukemia | year=2003 | pages=841-8 | volume=17 | issue=5  | id=PMID 12750695}}</ref>
 
===Refractory CLL===
"Refractory" CLL is a disease that no longer responds favorably to treatment. In this case more aggressive therapies, including [[lenalidomide]], flavopiridol, and bone marrow (stem cell) transplantation, are considered.<ref>{{cite web |url=http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page6 |title=Chronic Lymphocytic Leukemia (PDQ®) Treatment: Refractory Chronic Lymphocytic Leukemia|author=National Cancer Institute|accessdate=2007-09-04 |format= |work=}}</ref> 
Prolymphocytic transformation of CLL requires treatment with CHOP. 
 
===Monoclonal antibodies===
The monoclonal antibody, [[alemtuzumab]] (directed against [[CD52]]), may be used in patients with refractory, bone marrow-based disease.<!--
  --><ref name="Keating">{{cite journal | author=Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR | title=Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study | journal=Blood | year=2002 | pages=3554-61 | volume=99 | issue=10  | id=PMID 11986207}}</ref>  Alemtuzumab (Campath) is an anti-CD52 monoclonal antibody; CD52 is on all B & T lymphocytes.  Its use carries a RR = 33% with a CR = 2%.  Patients with pre-exisiting cytopenias show improvement in bone marrow function due to the lack of  stem cell (CD34) toxicity.  Its toxicity against T-cells can lead to significant immunosuppression and infectious complications (esp CMV reactivation).  Dose modifications are made for drug related cytopenias.  Premedications for its administration are necessary and (almost always) the first dose can be characterized by fever, rigors and nausea.  It is recommended to give benadryl, tylenol, hydrocortisone as well as Bactrin DS and Famciclovir. If a 17p del is found in a young CLL patient one could consider Alemtuzumab and early transplant.  It is otherwise approved for CLL refractory to alkylating agents and fludarabine. Ofatumumab is a novel monoclonal antibody against CD20 but targets a different epitope than Rituximab.  It is also different from Ritux in that it is a completely humanized anti-CD20 antibody whereas Ritux is a chimeric.  Ofatumumab (HuMax-CD20) appears to work well for patients who have lower CD20 levels on the surface of their lymphocytes.  Therefore it should be more effective than Ritux in treating CLL
(Ritux may not work as well because of low CD20 levels).  It is an active treatment option for CLL patients refractory to both fludarabine and alemtuzumab.
 
==Epidemiology==
CLL is a disease of the elderly and is rarely encountered in individuals under the age of 40. Thereafter the disease incidence increases with age. Of note, subclinical "disease" can be identified in up to 7-8% of individuals over the age of 70. That is, small clones of B cells with the characteristic CLL phenotype can be identified in many healthy elderly persons. The clinical significance of these cells is unknown.
 
==References==
{{Reflist|2}}
 
==External links==
*[http://www.cancer.gov/cancerinfo/pdq/treatment/CLL/patient/ US National Cancer Institute] - General information about CLL.


{{Hematology}}
{{Hematology}}
{{Hematological malignancy histology}}
{{Hematological malignancy histology}}
{{SIB}}
 
[[ar:ابيضاض الدم الليمفاوي المزمن]]
[[ar:ابيضاض الدم الليمفاوي المزمن]]
[[bn:দীর্ঘমেয়াদী লসিকাকোষীয় লিউকিমিয়া]]
[[bn:দীর্ঘমেয়াদী লসিকাকোষীয় লিউকিমিয়া]]
Line 174: Line 62:
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Mature chapter]]
[[Category:Mature chapter]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 16:24, 27 March 2019

Chronic lymphocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic lymphocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic lymphocytic leukemia On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic lymphocytic leukemia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic lymphocytic leukemia

CDC on Chronic lymphocytic leukemia

Chronic lymphocytic leukemia in the news

Blogs on Chronic lymphocytic leukemia

Directions to Hospitals Treating Chronic lymphocytic leukemia

Risk calculators and risk factors for Chronic lymphocytic leukemia

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shalinder Singh, M.B.B.S.[2], Haytham Allaham, M.D. [3]

Synonyms and keywords: CLL; Small Lymphocytic Lymphoma; B-cell Chronic Lymphocytic Leukemia; B cell Chronic Lymphocytic Leukemia

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic lymphocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice | Staging | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical therapy | Surgery | Primary prevention | Secondary prevention | Cost-effectiveness of therapy | Future or Investigational Therapies

Case Studies

Case #1

Template:Hematology

ar:ابيضاض الدم الليمفاوي المزمن bn:দীর্ঘমেয়াদী লসিকাকোষীয় লিউকিমিয়া de:Chronische lymphatische Leukämie ms:Leukemia limfosit kronik nl:Chronische lymfatische leukemie sr:Hronična limfatična leukemija fi:Krooninen lymfaattinen leukemia sv:Kronisk lymfatisk leukemi


Template:WikiDoc Sources